LARYNGEAL CANCER STAGE II

This adverse event was reported 19 times

LARYNGEAL CANCER STAGE II is most prevalent among patients taking these drugs:

# Drug Count Frequency
0 DEXTROMETHORPHAN HYDROBROMIDE, BUPROPION HYDROCHLORIDE 1 0.0003
1 OXCARBAZEPINE 1 0.0001
2 DABRAFENIB 1 0.0000
3 TRAMETINIB 1 0.0000
4 THALIDOMIDE 1 0.0000
5 MULTIVITAMIN 1 0.0000
6 RIBAVIRIN 1 0.0000
7 SULFASALAZINE 1 0.0000
8 BACLOFEN 1 0.0000
9 INTERFERON BETA-1A 2 0.0000
See all drugs enriched for association with LARYNGEAL CANCER STAGE II

LARYNGEAL CANCER STAGE II is most prevalent among patients taking these drug classes:

# Drug class Count Frequency
0 Folate Analog [EPC] 1 0.0000
1 Vitamin A [EPC] 1 0.0000
2 Nicotinic Acid [EPC] 1 0.0000
3 Antidote [EPC] 1 0.0000
4 Non-Standardized Food Allergenic Extract [EPC] 1 0.0000
5 Nucleoside Analog Antiviral [EPC] 1 0.0000
6 gamma-Aminobutyric Acid-ergic Agonist [EPC] 1 0.0000
7 Interferon beta [EPC] 2 0.0000
8 Aminosalicylate [EPC] 1 0.0000
9 Phosphodiesterase 4 Inhibitor [EPC] 1 0.0000
See all drug classes enriched for association with LARYNGEAL CANCER STAGE II